Researchers have made significant progress in developing a new treatment for wet age-related macular degeneration (wet AMD), a leading cause of vision loss in people over 50. EyePoint, Inc. announced that their investigational drug DURAVYU has shown a favorable safety profile in ongoing Phase 3 trials. This treatment aims to provide sustained relief from the condition, which often requires frequent injections that can be burdensome for patients.

For those looking to maintain their vision as they age, this could mean fewer trips to the doctor and a more manageable treatment routine. Current therapies typically require injections every two months, but DURAVYU is designed to be administered every six months. With over 900 participants enrolled in the trials, the results could potentially lead to a new standard of care that alleviates the treatment burden associated with wet AMD.

The research is still in the Phase 3 stage, which means it’s not yet proven for widespread use. The independent Data Safety Monitoring Committee has reviewed the safety data and recommended that the trials proceed as planned, reflecting confidence in the treatment’s safety and efficacy. Topline data from these trials is expected to be available in mid-2026, which will provide more insight into the effectiveness of DURAVYU compared to existing treatments.

While it’s too early to make any definitive claims about DURAVYU, those affected by wet AMD should stay informed about these developments. Consult with your healthcare provider about the latest treatments and participate in discussions about clinical trials that may be available to you.

Source: globenewswire.com